Cite
Karlsson C, Dahl H, Lundin J, et al. Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia. Blood Cancer J. 2011;1(6):e22doi: 10.1038/bcj.2011.20.
Karlsson, C., Dahl, H., Lundin, J., Rossmann, E., Brytting, M., Mellstedt, H., Linde, A., & Osterborg, A. (2011). Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia. Blood cancer journal, 1(6), e22. https://doi.org/10.1038/bcj.2011.20
Karlsson, C, et al. "Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia." Blood cancer journal vol. 1,6 (2011): e22. doi: https://doi.org/10.1038/bcj.2011.20
Karlsson C, Dahl H, Lundin J, Rossmann E, Brytting M, Mellstedt H, Linde A, Osterborg A. Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia. Blood Cancer J. 2011 Jun;1(6):e22. doi: 10.1038/bcj.2011.20. Epub 2011 Jun 10. PMID: 22829166; PMCID: PMC3255266.
Copy
Download .nbib